Exhibit 10.32

​

Portions of this Exhibit have been redacted because they are both (i) not material and (ii) would be competitively harmful if publicly disclosed or constitutes personal information. Information that was omitted has been noted in this document with a placeholder identified by the mark “[***]”.

​

FIRST AMENDMENT TO

EXECUTIVE EMPLOYMENT AGREEMENT

​

 This FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT (this “Amendment”) is entered into by and between Iovance Biotherapeutics, Inc., a Delaware corporation (the “Company”), and Daniel Gordon Kirby (the “Executive”) (collectively, the “Parties”), effective as of December 3, 2025 (the “Effective Date”).

​

WHEREAS, the Parties entered into that certain Executive Employment Agreement, effective as of January 25, 2025 (the “Employment Agreement”); and

​

WHEREAS, the Parties desire to amend the Employment Agreement as set forth herein;

​

NOW, THEREFORE, in consideration of the foregoing, the promises and obligations set forth below and for other good and valuable consideration, the receipt of which is hereby acknowledged by the Parties, the Parties agree and intend to be legally bound, as follows:

​

PSUs

​

​

​

​

[Signature Page Attached]

​

IT WITNESS WHEREOF, the Parties have executed this Amendment to be effective as of the Effective Date.

​

​